Vontobel Holding Ltd. Makes New $2.72 Million Investment in Arvinas, Inc. (NASDAQ:ARVN)

Vontobel Holding Ltd. bought a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 66,000 shares of the company's stock, valued at approximately $2,717,000. Vontobel Holding Ltd. owned about 0.12% of Arvinas as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in ARVN. China Universal Asset Management Co. Ltd. grew its stake in shares of Arvinas by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company's stock valued at $27,000 after buying an additional 674 shares during the last quarter. BluePath Capital Management LLC bought a new position in Arvinas during the 3rd quarter worth approximately $28,000. PNC Financial Services Group Inc. increased its stake in Arvinas by 1,015.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,383 shares of the company's stock worth $34,000 after purchasing an additional 1,259 shares during the period. Royal Bank of Canada lifted its position in Arvinas by 37.6% in the third quarter. Royal Bank of Canada now owns 1,230 shares of the company's stock valued at $54,000 after purchasing an additional 336 shares during the last quarter. Finally, Natixis purchased a new stake in shares of Arvinas during the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Buying and Selling at Arvinas

In other Arvinas news, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the sale, the insider now directly owns 67,516 shares in the company, valued at approximately $3,176,627.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Ronald Peck sold 1,699 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the transaction, the insider now directly owns 67,516 shares of the company's stock, valued at $3,176,627.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Sean A. Cassidy sold 1,702 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the transaction, the chief financial officer now owns 181,916 shares of the company's stock, valued at approximately $8,559,147.80. The disclosure for this sale can be found here. Insiders sold a total of 8,597 shares of company stock valued at $404,489 in the last three months. 2.55% of the stock is currently owned by corporate insiders.

Arvinas Trading Up 1.3 %

Arvinas stock traded up $0.43 during mid-day trading on Friday, hitting $34.72. The stock had a trading volume of 944,325 shares, compared to its average volume of 725,108. Arvinas, Inc. has a one year low of $13.57 and a one year high of $53.08. The firm has a market capitalization of $2.37 billion, a P/E ratio of -5.34 and a beta of 1.94. The firm's 50 day moving average is $43.27 and its 200 day moving average is $34.05.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.15) by ($1.38). The business had revenue of ($43.10) million during the quarter, compared to the consensus estimate of $38.91 million. Arvinas had a negative return on equity of 70.24% and a negative net margin of 185.09%. During the same period last year, the company earned ($1.56) EPS. As a group, equities research analysts forecast that Arvinas, Inc. will post -5.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARVN has been the topic of several analyst reports. Wedbush lifted their target price on shares of Arvinas from $33.00 to $59.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 28th. Leerink Partnrs reiterated an "outperform" rating on shares of Arvinas in a report on Thursday, February 22nd. HC Wainwright reduced their price target on Arvinas from $90.00 to $87.00 and set a "buy" rating on the stock in a report on Friday, April 12th. Barclays upped their price objective on shares of Arvinas from $26.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, February 29th. Finally, BMO Capital Markets increased their target price on Arvinas from $89.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $59.73.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.